Emmecell

📍 Menlo Park, United States👥 10 employees💰 Last funded Feb 2023
Biotechnology Research🌐 emmecell.com
Website LinkedIn
Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately-held, clinical stage biotechnology company developing cell-based therapies. Emmecell’s platform technology leverages magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue. Our lead product EO2002 is a cell therapy for treatment for corneal edema, the most common indication for corneal transplantation. Cell Manufacturing and Production LLC (CellMP) was founded in 2018 and is a subsidiary of Emmecell providing GMP manufacturing services in Menlo Park, CA.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Emmecell?
Emmecell has 1 investors on record on gritt.io.
When did Emmecell last raise funding?
The most recent investment in Emmecell recorded on gritt.io was in February 2023.
What industry is Emmecell in?
Emmecell operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Emmecell based?
Emmecell is headquartered in Menlo Park, United States.